How do StarDrop and LiveDesign compare?
Finding the right fit There’s no one-size-fits-all solution when it comes to data visualisation and analysis tools for drug development…
In this paper, we describe an extended benchmark for non-cognate docking of macrocyclic ligands, and the superior performance of Surflex-Dock against other structure-based design methods for pose prediction.
So-called “cross-docking” is the prediction of the bound configuration of small-molecule ligands that differ from the cognate ligand of a protein co-crystal structure. This is a much more challenging problem than re-docking the cognate ligand, particularly when the new ligand is structurally dissimilar from prior known ones.
We have updated the previously introduced PINC (“PINC Is Not Cognate”) benchmark which introduced the idea of temporal segregation to measure cross-docking performance. The temporal set encompasses 846 future ligands for ten targets based on information from the earliest 25% of X-ray co-crystal structures known for each target.
Here, we extend the benchmark to include thirteen targets where the bound poses of 128 macrocyclic ligands are to be predicted based on knowledge from structures of bound non-macrocyclic ligands. Performance was roughly equivalent for both the temporally-split non-macrocyclic ligand set and the macrocycle prediction set.
Using standard and fully automatic protocols for the Surflex-Dock and ForceGen methods, across the combined 974 non-macrocyclic and macrocyclic ligands, the top-scoring pose family was correct 68% of the time, with the top-two pose families achieving a 79% success rate. Correct poses among all those predicted were identified 92% of the time. These success rates far exceeded those observed for the alternative methods AutoDock Vina and Gnina on both sets.
Visit our webpage to learn about the full BioPharmics platform for 3D molecular design. Alternatively, join our webinar on ‘Molecular docking: Extrapolating to new scaffolds with Surflex-Dock‘.
Finding the right fit There’s no one-size-fits-all solution when it comes to data visualisation and analysis tools for drug development…
To answer this question, we first have to define ‘improve’. There are two main ways in which AI can have…
What’s the purpose of a predictive model? What’s the value of predictive models for drug discovery? Most of the undergraduate…